• Mon news: AZ obesity pill. 50% of drug shortages last at least 2 years. Pharmas and IRA lawsuit appeals. Novo-Ascendis biobucks deal. Wegovy reduces all-cause hospital admissions. See more on our front page

A bad move by Allergan

Quote










The truth is there are providers already using testosterone to treat uterine fybroids. Now, the question is how will Allergan get the study completed and convince the FDA?
 




anonymous said:
The truth is there are providers already using testosterone to treat uterine fybroids. Now, the question is how will Allergan get the study completed and convince the FDA?
Click to expand...
This is a great deal, BS will throw the vast array Allergan R&D talent at this and we will add another fine product to the portfolio.......oh no wait.....doh!
 








This deal is like all the other M&A deals that Saunders has spent money on. It's a roll of the dice. Potentially a smart move since Esmya could have liver issues and if they are able to develop Repros' drug then they might have made a wise purchase. Payback could be huge!
 




Prospects dim for European approval of Repros' enclomiphene for secondary hypogonadism.

Any waste of $26Million by Saunders. Is the board paying attention to this guys stupidiity??????
 




















Top Bottom
Back
Quote